Roche Holding AG (SWX:RO)
Switzerland · Delayed Price · Currency is CHF 265.40
-1.80 (-0.67%)
Sep 26, 2025, 5:31 PM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B
Revenue Growth
+4.80%
P/S Ratio
3.43
Revenue / Employee
614.90K
Employees
103,249
Market Cap
217.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 43.89B |
| Lonza Group AG | 7.09B |
| Galderma Group AG | 3.73B |
| Alcon | 7.97B |
| Sandoz Group AG | 8.42B |
| Straumann Holding AG | 2.58B |
| Sonova Holding AG | 3.87B |
Roche Holding AG News
- 2 days ago - Roche points to U.S. plans after Trump pharma tariff announcement - Reuters
- 3 days ago - Kodiak gains as Barclays upgrades on Roche data for eye disease drug - Seeking Alpha
- 3 days ago - Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial - CNBC
- 4 days ago - Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025 - GlobeNewsWire
- 4 days ago - Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025 - Business Wire
- 5 days ago - Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon? - Seeking Alpha
- 6 days ago - Roche Holding AG - Special Call - Seeking Alpha
- 6 days ago - Roche Targets Top Spot In Weight Loss Drug Market - Benzinga